Cancer News and Research

Latest Cancer News and Research

June Cold Spring Harbor Protocols features electrophoresis in RNA analysis and avian embryos

Gel electrophoresis is one of the most important and frequently used techniques in RNA analysis. Electrophoresis is used for RNA detection, quantification, purification by size and quality assessment. Gels are involved in a wide variety of methods including northern blotting, primer extension, footprinting and analyzing processing reactions. The two most common types of gels are polyacrylamide and agarose.

5 Jun 2010

Scientific, ethical issues involved in studies of drug safety after FDA approval to be evaluated

The director and a core faculty member of the Johns Hopkins Berman Institute of Bioethics have been appointed co-chairs of an Institute of Medicine committee that will evaluate the scientific and ethical issues involved in studies of drug safety after FDA approval.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

$2M federal grant to double computing power at Southwest Foundation For Biomedical Research

The "computer ranch" at the Southwest Foundation for Biomedical Research (SFBR), one of the world's largest clusters of computers for human gene research, will more than double in size this summer, thanks to a $2 million federal grant that will speed the pace of discovery at the Foundation's AT&T Genomics Computing Center.

5 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

COMMD1 protein restrains metastatic potential of invasive cancer cell line: Researchers

Researchers at UT Southwestern Medical Center have determined that cancer cells lacking a key protein are more invasive and more likely to metastasize, providing a possible drug target to combat certain tumor types.

5 Jun 2010

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

NewYork-Presbyterian Hospital is the only tri-state-area hospital listed on the 2010 U.S.News & World Report "America's Best Children's Hospitals" "Honor Roll" and one of only eight children's hospitals in the nation to be ranked in all 10 clinical specialties. NewYork-Presbyterian provides children's health services at two major centers: NewYork-Presbyterian/Morgan Stanley Children's Hospital and the Phyllis and David Komansky Center for Children's Health.

5 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago (Abstract #8588).

5 Jun 2010

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

5 Jun 2010

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes to remain convertible through July 6, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 (the "notes") are convertible at the option of the holders and will remain convertible at least through July 6, 2010, as provided for in the Indenture governing the notes.

5 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson. The study will be presented at the 2010 ASCO Annual Meeting in Chicago (Abstract #2037).

5 Jun 2010

Green tea component reduces leukemia cells in patients with CLL

An extract of green tea appears to have clinical activity with low toxicity in chronic lymphocytic leukemia (CLL) patients who used it in a phase II clinical trial, say researchers at Mayo Clinic.

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

5 Jun 2010

HHF to open Terni Human Health Bioscience Institute

The Human Health Foundation, a nonprofit organization founded in 2006 to develop and fund biomedical research in Italy, will open the Terni Human Health Bioscience Institute for the investigation of breast, brain and lung cancer on June 7th in Terni, Italy.

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

Cancer News and Research

Latest Cancer News and Research

June Cold Spring Harbor Protocols features electrophoresis in RNA analysis and avian embryos

Scientific, ethical issues involved in studies of drug safety after FDA approval to be evaluated

New clinical research findings on oncology to be highlighted at ASCO 2010

$2M federal grant to double computing power at Southwest Foundation For Biomedical Research

USC to present promising new findings in cancer research at 2010 ASCO

COMMD1 protein restrains metastatic potential of invasive cancer cell line: Researchers

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

Celgene reports initial data from investigator-initiated study of REVLIMID

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

OSI Pharmaceuticals' 2% Senior Subordinated Notes to remain convertible through July 6, 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Green tea component reduces leukemia cells in patients with CLL

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

HHF to open Terni Human Health Bioscience Institute

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in